2012;27:783–92.PubMedCrossRef 16. Moldoveanu Z, Wyatt RJ, Lee JY, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 2007;71:1148–54.PubMedCrossRef 17. Suzuki H, Moldoveanu Z, Hall S, et al. IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin

Invest. 2008;118:629–39.PubMedCentralPubMed 18. Suzuki H, Fan R, Zhang Z, et al. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. J Clin Invest. 2009;119:1668–77.PubMedCentralPubMed SB525334 cost 19. Novak J, Julian BA, Tomana M, et al. IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy. Semin Nephrol. 2008;28:78–87.PubMedCentralPubMedCrossRef 20. Suzuki H,

Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795–803.PubMedCrossRef 21. Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol. 2012;23:1579–87.PubMedCrossRef 22. Ieiri N, Hotta O, Sato T, et al. Significance of the duration of nephropathy for achieving clinical remission in patients with IgA nephropathy treated by tonsillectomy and steroid pulse therapy. Clin Exp Nephrol. 2012;16:122–9.PubMedCrossRef 23. Hotta O, Furuta T, Chiba S, et al. Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis. 2002;39:493–502.PubMedCrossRef 24. Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and Cyclosporin A chemical structure antiglycan antibodies. J Clin Invest. 1999;104:73–81.PubMedCentralPubMedCrossRef

25. Matousovic K, Novak J, Yanagihara T, et al. IgA1-containing immune complexes in the urine of IgA nephropathy patients. Nephrol Dial Transplant. 2006;21:2478–84.PubMedCrossRef 26. Hollander M, Wolfe DA. CP-868596 cost Nonparametric statistical methods. 2nd ed. Hoboken: Wiley-Interscience; 1999. 27. Clarkson AR, Seymour AE, Thompson AJ, et al. IgA nephropathy: Megestrol Acetate a syndrome of uniform morphology, diverse clinical features and uncertain prognosis. Clin Nephrol. 1977;8:459–71.PubMed 28. D’Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64:709–27.PubMed 29. Gharavi AG, Moldoveanu Z, Wyatt RJ, et al. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. J Am Soc Nephrol. 2008;19:1008–14.PubMedCrossRef 30. Suzuki H, Suzuki Y, Narita I, et al. Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol. 2008;19:2384–95.PubMedCrossRef 31. Kajiyama T, Suzuki Y, Kihara M, et al. Different pathological roles of toll-like receptor 9 on mucosal B cells and dendritic cells in murine IgA nephropathy. Clin Dev Immunol. 2011;2011:819646. doi:10.​1155/​2011/​819646 PubMedCentralPubMedCrossRef 32. Sato D, Suzuki Y, Kano T, et al.